Status:
COMPLETED
Patterns of Prescribing and Monitoring of Palbociclib
Lead Sponsor:
Rush University Medical Center
Conditions:
Metastatic Breast Cancer
Advanced Breast Cancer
Eligibility:
All Genders
18-50 years
Brief Summary
The purpose of this study is to determine if patients with ER+, human epidermal growth factor 2 negative (HER2-), advanced breast cancer are receiving dosing adjustments and monitoring based on manufa...
Detailed Description
This study was a retrospective, single-center study that included women receiving palbociclib for the treatment of ER+, HER2- advanced breast cancer. Exclusion criteria were the presence of brain meta...
Eligibility Criteria
Inclusion
- women at least 18 years old
- ER+, HER2- advanced breast cancer
- receiving palbociclib
Exclusion
- brain metastases
- on palbociclib clinical trial
Key Trial Info
Start Date :
February 3 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2016
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT03285568
Start Date
February 3 2015
End Date
December 30 2016
Last Update
March 31 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.